Poster Discussion Round:
195. Clostridium difficile
Saturday, October 5, 2013: 12:30 PM-2:00 PM
Room: The Moscone Center: Poster Hall C

Learning Objectives:

Sessions on new, unpublished information presented as posters in the areas of HIV medicine, antimicrobials, bacterial diseases, fungal diseases, public health, pediatric infectious diseases, virology, and vaccines will be critiqued by experts in each of these fields.  It is assumed that participants know or are familiar with the general principles of the epidemiology, pathogenesis, prevention, and therapy of infectious diseases.  At the completion of the session, participants will have gained knowledge on emerging information in infectious diseases with the ability to place this information in the context of prior published data.

Target Audience: academicians, clinicians, epidemiologists, fellows, health care workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Tracks: Adult ID, Epidemiology and Infection Control, Pediatric ID

Group Leader:  Dale Gerding, MD, FIDSA, Hines Veterans Affairs Hospital and Loyola University Stritch School of Medicine


12:30 PM
Group Leader
Dale Gerding, MD, FIDSA

CME Credits:

ACPE Credits:

ACPE Number:


D. Gerding, ViroPharma: Consultant and Patents licensed, Consulting fee and Patent license continuation fee
Merck: Scientific Advisor, Consulting fee
Actelion: Scientific Advisor, Consulting fee
Sanofi Pasteur: Scientific Advisor, Consulting fee
Cangene: Consultant, Consulting fee
Roche: Consultant, Consulting fee
Novartis: Consultant, Consulting fee
Cubist: Consultant, Consulting fee
Rebiotix: Consultant, Consulting fee
GOJO: Grant Investigator, Research grant
Cepheid: Grant Investigator, Research grant

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.